Standard BioTools Inc (NASDAQ: LAB) on Monday, soared 1.19% from the previous trading day, before settling in for the closing price of $1.68. Within the past 52 weeks, LAB’s price has moved between $1.21 and $3.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -0.06%. The company achieved an average annual earnings per share of 56.74%. With a float of $359.12 million, this company’s outstanding shares have now reached $371.15 million.
Let’s determine the extent of company efficiency that accounts for 539 employees. In terms of profitability, gross margin is 46.67%, operating margin of -85.69%, and the pretax margin is -87.0%.
Standard BioTools Inc (LAB) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Standard BioTools Inc is 3.24%, while institutional ownership is 72.57%. The most recent insider transaction that took place on Sep 09 ’24, was worth 91,725. Before that another transaction happened on Aug 27 ’24, when Company’s Director bought 250,000 for $2.19, making the entire transaction worth $546,750. This insider now owns 54,025,821 shares in total.
Standard BioTools Inc (LAB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 56.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.06% during the next five years compared to 8.72% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Standard BioTools Inc (LAB) is currently performing well based on its current performance indicators. A quick ratio of 3.53 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.90, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Looking closely at Standard BioTools Inc (NASDAQ: LAB), its last 5-days average volume was 1.69 million, which is a drop from its year-to-date volume of 2.43 million. As of the previous 9 days, the stock’s Stochastic %D was 9.36%. Additionally, its Average True Range was 0.10.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 35.25%, which indicates a significant increase from 15.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.57% in the past 14 days, which was lower than the 100.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9276, while its 200-day Moving Average is $2.2341. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.7500. Second resistance stands at $1.8000. The third major resistance level sits at $1.8400. If the price goes on to break the first support level at $1.6600, it is likely to go to the next support level at $1.6200. Should the price break the second support level, the third support level stands at $1.5700.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
Market capitalization of the company is 630.96 million based on 370,421K outstanding shares. Right now, sales total 106,340 K and income totals -74,660 K. The company made 37,210 K in profit during its latest quarter, and -45,720 K in sales during its previous quarter.
